Pascal Hickey has over 20 years’ international experience in pharmaceutical development and operations. He has held a range of R&D management responsibilities in innovative and rapidly growing biotechnology companies.  He has over 10 years' experience in allergy  and prior to joining Aravax, Dr Hickey was Vice President Early Development at Circassia Pharmaceuticals (UK).  

Prior appointments include roles at Chiron and PowderJect Technologies. Dr Hickey received his Bachelor of Pharmacy from the Victorian College of Pharmacy and PhD from Monash University, Australia.

Sara Prickett has over 15 years’ research experience in cellular immunology and was responsible for the preclinical development of Aravax's peanut allergy therapy. Prior to Aravax, Dr Prickett held senior research posts at Alfred Health and Monash University where she played a major role in the research underpinning the peanut allergy therapy being developed by Aravax. She is a co-inventor, and co-founder of the company.

Dr Prickett received her Bachelor of Science from Sheffield University and PhD from Imperial College, London. 

Paul Laidler has over 20 years' pharmaceutical development experience having held a number of roles within large Pharmaceutical companies including Zeneca/AstraZeneca and a number of rapidly developing biotechnology companies including PowderJect Technologies, Chiron Vaccines, PowderMed and most recently Circassia Pharmaceuticals. Prior to setting up as an independent consultant, Dr Laidler was Vice President of Pharmaceutical Sciences at Circassia Pharmaceuticals.

Dr Laidler received both his Bachelor of Pharmacy and PhD degrees from King’s College London.

Judy Bingham has over 25 years' clinical development and regulatory strategy experience in the Australian  and international pharmaceutical and biotechnology industries, including 10 years as Senior Director, Consulting Services at Kendle International (now Syneos Health) and pharmaceutical companies Faulding (now Pfizer) and CSL.

Judy has a Bachelor of Pharmacy from Victorian College of Pharmacy, is a Fellow of the Society of Hospital Pharmacists of Australia and has a Masters in Health Science from Latrobe University. 

Matthew Moyle is a biopharma veteran with extensive experience in the discovery and development of novel therapeutic agents. He has led R&D groups at Boehringer Ingelheim, Amgen and Tanox, among others, resulting in the delivery of more than 20 drug candidates that have advanced to clinical testing, and the approval thus far of two products.
 

Prior to joining the Aravax team, Dr Moyle was Chief Scientific Officer at AnaptysBio. Dr Moyle received his BSc and PhD degrees in Biochemistry from the University of Toronto and completed postdoctoral studies at Genentech.